Dissecting Clonal Heterogeneity in AML

Jan Jacob Schuringa; Constanze Bonifer

doi:10.1016/j.ccell.2020.11.011

Dissecting Clonal Heterogeneity in AML

Cancer Cell. 2020 Dec 14;38(6):782-784. doi: 10.1016/j.ccell.2020.11.011.

Authors

Jan Jacob Schuringa¹, Constanze Bonifer²

Affiliations

¹ Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands. Electronic address: j.j.schuringa@umcg.nl.
² Institute for Cancer and Genomic Sciences, College of Medicine and Dentistry, University of Birmingham, B15 2TT Birmingham, UK. Electronic address: c.bonifer@bham.ac.uk.

PMID: 33321087
DOI: 10.1016/j.ccell.2020.11.011

Abstract

Using targeted single-cell DNA sequencing approaches, two articles in Nature and Nature Communications have now firmly established that acute myeloid leukemia is a highly dynamic oligoclonal disease. Clonal evolution during disease progression and therapy occurs in both linear and branched trajectories, with a clear order of mutational events.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Clonal Evolution
Disease Progression
Humans
Leukemia, Myeloid, Acute*
Mutation
Sequence Analysis, DNA

Abstract

Publication types

MeSH terms

Grants and funding